Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 30
Filtrer
1.
J Drugs Dermatol ; 23(4): e120, 2024 04 01.
Article de Anglais | MEDLINE | ID: mdl-38564389

RÉSUMÉ

It is the realization of a long-dreamed aspiration to create a university that would advance global health delivery by training a new generation of global health leaders who are equipped to not just build, but sustain effective and equitable health systems.


Sujet(s)
Dermatologie , Humains , Rwanda
3.
Skin Therapy Lett ; 28(4): 1-3, 2023 07.
Article de Anglais | MEDLINE | ID: mdl-37440610

RÉSUMÉ

Botulinum toxin A (BoNTA) is produced by Clostridium botulinum and widely used for aesthetic indications requiring neuromuscular blockade. For dynamic facial lines, BoNTA is effective and safe, but also temporary, requiring repeat injections approximately every 3-4 months for maintenance of effects. There is a desire by both patients and providers for a longer-lasting neurotoxin to prevent periods of suboptimal correction. Approved by the US Food and Drug Administration (FDA) in September 2022, daxibotulinumtoxinA for injection (DAXI or Daxxify™) is the first long-lasting BoNTA formulated with a 150-kDa BoNTA (RTT150) and proprietary stabilizing excipient peptide (RTP004) in place of human serum albumin. DAXI is approved for treatment of moderate to severe glabellar lines. The median duration of effect was 6 months and results lasted as long as 9 months in some patients. Its unique formulation and prolonged effectiveness positions DAXI as a safe, novel BoNTA for improved durability and patient satisfaction.


Sujet(s)
Toxines botuliniques de type A , Vieillissement de la peau , Humains , Toxines botuliniques de type A/usage thérapeutique , Face , Neurotoxines/effets indésirables , Satisfaction des patients
5.
Int J Dermatol ; 58(10): 1107-1111, 2019 Oct.
Article de Anglais | MEDLINE | ID: mdl-30816574

RÉSUMÉ

Fiberglass dermatitis is a common form of occupational irritant contact dermatitis. Individuals experience a negative reaction to fiberglass fragments because of mechanical irritation. This review comprehensively analyzes the information in the existing literature on fiberglass dermatitis. Recognizing the different environmental risks factors for acquiring fiberglass dermatitis is necessary for better diagnosis and prevention. In addition to the identification of high-risk populations exposed to fiberglass particles, the common clinical presentation and preventive measures that can reduce the risk of acquiring fiberglass dermatitis are thoroughly discussed.


Sujet(s)
Dermatite irritative/diagnostic , Dermatite professionnelle/diagnostic , Verre , Exposition professionnelle/effets indésirables , Administration par voie cutanée , Administration par voie orale , Dermatite irritative/traitement médicamenteux , Dermatite irritative/étiologie , Dermatite irritative/prévention et contrôle , Dermatite professionnelle/traitement médicamenteux , Dermatite professionnelle/étiologie , Dermatite professionnelle/prévention et contrôle , Glucocorticoïdes/administration et posologie , Antihistaminiques/administration et posologie , Humains , Microscopie confocale , Tests épicutanés , Vêtements de protection , Facteurs de risque , Peau/imagerie diagnostique
6.
Pediatr Dermatol ; 36(1): e41-e43, 2019 Jan.
Article de Anglais | MEDLINE | ID: mdl-30318648

RÉSUMÉ

Disseminated congenital pyogenic granuloma (DCPG) is an uncommon condition. Individual lesions of DCPG share clinical and histologic similarities with infantile hemangioma (IH); endothelial glucose transporter 1 (GLUT-1), which is highly expressed in IH but generally not in pyogenic granulomas (PG), is an important diagnostic tool. Treatment for DCPG remains difficult. We describe a case of DCPG effectively treated with propranolol.


Sujet(s)
Antagonistes bêta-adrénergiques/usage thérapeutique , Granulome pyogénique/traitement médicamenteux , Propranolol/usage thérapeutique , Administration par voie orale , Granulome pyogénique/congénital , Humains , Nourrisson , Mâle , Peau/anatomopathologie
7.
J Am Acad Dermatol ; 79(5): 935-944, 2018 Nov.
Article de Anglais | MEDLINE | ID: mdl-29902544

RÉSUMÉ

BACKGROUND: Adipose tissue has classically functioned as a filler in restoring facial volume. Adipose tissue is also rich in stem cells, which may have a role in regenerative medicine. OBJECTIVE: To summarize the literature on the clinical uses of adipose tissue in scarring, wound healing, and hair growth and determine whether evidence exists for changes in clinical practice in dermatology. METHODS: We utilized the Preferred Reporting Items for Systemic Reviews and Meta-Analyses to conduct the review. The PubMed search engine was used to assess the available literature on adipose tissue in scarring, wound healing, and hair growth. RESULTS: A total of 13 studies matched our inclusion criteria; 6 of the 7 studies on scar treatment, all 3 studies on wound healing, and all 3 studies on hair growth demonstrated improved outcomes with adipose tissue treatments. LIMITATIONS: The literature supporting the use of adipose tissue is limited to case series, cohort studies, and small randomized controlled trials, which have an overall low level of evidence. CONCLUSION: The existing evidence for adipose tissue as a treatment option in scarring, wound healing, and hair growth is not strong enough to justify changes to current clinical practice. The literature does provide evidence for future large randomized clinical trials.


Sujet(s)
Adipocytes/transplantation , Tissu adipeux/transplantation , Rajeunissement/physiologie , Chirurgie plastique/méthodes , Cicatrice hypertrophique/chirurgie , Dermatologie/méthodes , Esthétique , Femelle , Humains , Mâle , Transplantation autologue
8.
Skin Appendage Disord ; 4(1): 1-11, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29457005

RÉSUMÉ

Androgenetic alopecia (AGA) is a hair loss disorder affecting 80% of men and 50% of women throughout their lifetime. Therapies for AGA are limited and there is no cure. There is a high demand for hair restoration. Platelet-rich plasma (PRP), a treatment modality shown to promote wound healing, has also been explored as a treatment for AGA. This literature review was conducted to assess the effectiveness of PRP treatment for AGA. Twelve studies conducted from 2011 to 2017 were evaluated and summarized by study characteristics, mode of preparation, and treatment protocols. A total of 295 subjects were given PRP or control treatment in these studies, and evaluated for terminal hair density, hair quality, anagen/telogen hair ratio, keratinocyte proliferation, blood vessel density, etc. Some studies also provided subject self-assessment reports. Most of the studies reviewed showed effectiveness of PRP in increasing terminal hair density/diameter. Additional investigations are needed to determine the optimal treatment regimen for high efficacy of PRP in AGA.

9.
Lasers Med Sci ; 33(3): 675-681, 2018 Apr.
Article de Anglais | MEDLINE | ID: mdl-29322402

RÉSUMÉ

Hyperhidrosis o`ccurs when the body produces sweat beyond what is essential to maintain thermal homeostasis. The condition tends to occur in areas marked by high-eccrine density such as the axillae, palms, and soles and less commonly in the craniofacial area. The current standard of care is topical aluminum chloride hexahydrate antiperspirant (10-20%), but other treatments such as anticholinergics, clonidine, propranolol, antiadrenergics, injections with attenuated botulinum toxin, microwave technology, and surgery have been therapeutically implicated as well. Yet, many of these treatments have limited efficacy, systemic side effects, and may be linked with significant surgical morbidity, creating need for the development of new and effective therapies for controlling excessive sweating. In this literature review, we examined the use of lasers, particularly the Neodynium:Yttrium-Aluminum-Garnet (Nd:YAG) and diode lasers, in treating hyperhidrosis. Due to its demonstrated effectiveness and limited side effect profile, our review suggests that Nd:YAG laser may be a promising treatment modality for hyperhidrosis. Nevertheless, additional large, randomized controlled trials are necessary to confirm the safety and efficacy of this treatment option.


Sujet(s)
Aisselle/effets des radiations , Hyperhidrose/radiothérapie , Lasers , Humains
10.
Am J Clin Dermatol ; 19(2): 237-252, 2018 Apr.
Article de Anglais | MEDLINE | ID: mdl-28791605

RÉSUMÉ

Unwanted facial and body hair presents as a common finding in many patients, such as females with hirsutism. With advances in laser and light technology, a clinically significant reduction in hair can be achieved in patients with light skin. However, in patients with darker skin, Fitzpatrick skin types (FST) IV-VI, the higher melanin content of the skin interferes with the proposed mechanism of laser-induced selective photothermolysis, which is to target the melanin in the hair follicle to cause permanent destruction of hair bulge stem cells. Many prospective and retrospective studies have been conducted with laser and light hair-removal devices, but most exclude patients with darkly pigmented skin, considering them a high-risk group for unwanted side effects, including pigmentation changes, blisters, and crust formation. We reviewed the published literature to obtain studies that focused on hair reduction for darker skin types. The existing literature for this patient population identifies longer wavelengths as a key element of the treatment protocol and indicates neodymium-doped yttrium aluminum garnet (Nd:YAG), diode, alexandrite, and ruby lasers as well as certain intense pulsed light sources for safe hair reduction with minimal side effects in patients with FST IV-VI, so long as energy settings and wavelengths are appropriate. Based on the findings in this review, safe and effective hair reduction for patients with FST IV-VI is achievable under proper treatment protocols and energy settings.


Sujet(s)
Follicule pileux/effets des radiations , Hirsutisme/thérapie , Thérapie laser/méthodes , Lasers à solide/usage thérapeutique , Pigmentation de la peau/effets des radiations , Protocoles cliniques , Poils , Follicule pileux/métabolisme , Épilation/instrumentation , Épilation/méthodes , Humains , Thérapie laser/effets indésirables , Thérapie laser/instrumentation , Mélanines/métabolisme , Mélanines/effets des radiations , Sélection de patients , Peau , Résultat thérapeutique
11.
Dermatol Ther ; 31(1)2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29193602

RÉSUMÉ

Acne vulgaris is a chronic disease of the pilosebaceous units presenting as inflammatory or noninflammatory lesions in individuals of all ages. The current standard of treatment includes topical formulations in the forms of washes, gels, lotions, and creams such as antibiotics, antibacterial agents, retinoids, and comedolytics. Additionally, systemic treatments are available for more severe or resistant forms of acne. Nevertheless, these treatments have shown to induce a wide array of adverse effects, including dryness, peeling, erythema, and even fetal defects and embolic events. Zinc is a promising alternative to other acne treatments owing to its low cost, efficacy, and lack of systemic side effects. In this literature review, we evaluate the effectiveness and side-effect profiles of various formulations of zinc used to treat acne.


Sujet(s)
Acné juvénile/traitement médicamenteux , Produits dermatologiques/administration et posologie , Gluconates/administration et posologie , Peau/effets des médicaments et des substances chimiques , Acétate de zinc/administration et posologie , Sulfate de zinc/administration et posologie , Acné juvénile/diagnostic , Administration par voie cutanée , Administration par voie orale , Produits dermatologiques/effets indésirables , Association médicamenteuse , Femelle , Gluconates/effets indésirables , Humains , Mâle , Peau/anatomopathologie , Résultat thérapeutique , Acétate de zinc/effets indésirables , Oxyde de zinc/administration et posologie , Sulfate de zinc/effets indésirables
12.
Skin Res Technol ; 24(2): 274-277, 2018 May.
Article de Anglais | MEDLINE | ID: mdl-29171081

RÉSUMÉ

BACKGROUND: Mexican mestizo population has a pluriethnic mixture of Amerindian, European and African ancestry, predominant in most Latin American countries. Until now, there are no reports about hair characteristics in this population, necessary to define normal values, for hair diseases evaluation and comparison among other ethnic groups. METHODS: The VivoSight® swept-source multibeam optical coherence tomography system was used to evaluate hair diameter and shape in 30 females. Three hair samples from each volunteer were measured transversely along three distances, generating nine cross-sectional images, two measurements per image and 18 measurements per patient for a total of 540 diameter measurements. RESULTS: Minimum hair diameter (n = 540) was 0.06 mm while maximum was 0.14 mm. Mean diameter was 0.10 ± 0.01 mm as compared with Asian hair, which ranges from 0.08 mm to 0.12 mm. On morphological analysis, Mexican Mestizo hair tends to have a round shape with homogenous diameters, resembling Caucasian and Asian hair. CONCLUSION: Mexican hair is similar to Asian hair in diameter and shape and can be classified as 'thick' hair, which make it more resistant and with more volume. Cosmetic products intended to improve hair care in this population must to consider this characteristic.


Sujet(s)
Poils/anatomie et histologie , Adolescent , Adulte , Études transversales , Femelle , Poils/imagerie diagnostique , Volontaires sains , Humains , Indiens d'Amérique Nord/ethnologie , Mexique/ethnologie , Adulte d'âge moyen , Tomographie par cohérence optique/méthodes , /ethnologie , Jeune adulte
13.
Drug Saf Case Rep ; 4(1): 19, 2017 Nov 14.
Article de Anglais | MEDLINE | ID: mdl-29138996

RÉSUMÉ

Tyrosine kinase inhibitors have revolutionized the chemotherapy arena as targeted therapies for a multitude of malignancies. They are more selective than conventional chemotherapy, and often elicit fewer systemic adverse events, however toxicities still exist. Cutaneous toxicities are common and their management presents a novel challenge to physicians and patients. Ponatinib is a third-generation tyrosine kinase inhibitor increasingly reported to cause cutaneous eruption. A 50-year-old woman with a history of chronic myelogenous leukemia presented with a 4-month history of worsening atrophic and ichthyosiform pink plaques involving the axillae, thighs and abdomen; red patches were also observed on the cheeks and forehead. She was started on the third-generation, ponatinib, 5 months earlier because of disease refractory to previous therapies including interferon, imatinib, dasatinib and bosutinib. A skin biopsy revealed perifollicular fibrosis, alternating orthokeratosis and parakeratosis, and a sparse perivascular lymphocytic infiltrate consistent with a pityriasis rubra pilaris-like reaction. Topical tretinoin 0.025% cream was initiated, resulting in resolution within 3 weeks without discontinuation of ponatinib. A review of previous reports identified significant similarities among the ponatinib-induced drug reactions. Here, we highlight not only that cutaneous eruptions occur on ponatinib therapy, but that the dermatologic manifestations are characteristic and unique, and benefit from retinoid therapy, without requiring interruption of vital chemotherapy.

19.
G Ital Dermatol Venereol ; 152(4): 360-372, 2017 Aug.
Article de Anglais | MEDLINE | ID: mdl-28358185

RÉSUMÉ

Acne is a chronic disease of the pilosebaceous units, presenting as inflammatory or noninflammatory lesions, affecting primarily the face but also the back and chest. The mainstay of treatment remains topical retinoids, benzoyl peroxide, azelaic acid, antibiotics, and isotretinoin, many of which result in poor compliance, lack of durable remission, and incur adverse effects. The use of lasers to treat acne is continuously increasing because of their minimal complications, limited number of office-based treatments required, potential benefits of simultaneously treating acne scarring, and the rapid onset of results. The 1450 nm diode laser, 585- and 595-nm pulsed dye lasers (PDLs), near infrared diode lasers, 1320 nm Nd:YAG laser, 532 nm potassium titanyl phosphate laser, 1064 nm long-pulsed Nd:YAG laser, 1540 nm Erbium (Er):Glass Laser, and the 1550 nm Er:Glass fractional laser are among the most common lasers used to treat acne and acne scarring. These lasers target the underlying causes of acne including the colonization of Priopionibacterium acnes, high levels of sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, and back. We review the efficacy and side effect profiles of various lasers used to treat acne.


Sujet(s)
Acné juvénile/thérapie , Cicatrice/thérapie , Thérapie laser/méthodes , Acné juvénile/anatomopathologie , Cicatrice/étiologie , Produits dermatologiques/administration et posologie , Produits dermatologiques/usage thérapeutique , Humains , Thérapie laser/effets indésirables , Observance par le patient , Résultat thérapeutique
20.
Dermatol Ther ; 30(5)2017 Sep.
Article de Anglais | MEDLINE | ID: mdl-28220628

RÉSUMÉ

Safe and effective treatment options for acne vulgaris are needed to address side effects and increasing rates of antibiotic resistance from current treatments. Nicotinamide is a vitamin with potent anti-inflammatory properties that could offer a potential treatment option. We aim to summarize the relevant literature on the role of nicotinamide in acne vulgaris and discuss the next steps necessary to move this approach into clinical practice. We searched PubMed for clinical studies using nicotinamide for treatment of acne vulgaris. We summarized the 10 studies that met our search criteria. Six of eight studies using topical nicotinamide led to a significant reduction in acne compared with the patient's baseline or performed similarly to another standard-of-care acne treatment. Both studies using an oral supplement containing nicotinamide resulted in a significant reduction in acne compared with baseline. No major adverse side effects were noted. Our review suggests that topical and oral nicotinamide has an unclear effect on acne vulgaris due to the limited nature of the available literature. Additional studies are needed comparing nicotinamide to other first-line acne treatments and evaluating the efficacy and side effect profile of nicotinamide over an extended period of time.


Sujet(s)
Acné juvénile/traitement médicamenteux , Anti-inflammatoires/administration et posologie , Nicotinamide/administration et posologie , Acné juvénile/anatomopathologie , Administration par voie cutanée , Administration par voie orale , Antibactériens/administration et posologie , Antibactériens/pharmacologie , Anti-inflammatoires/effets indésirables , Anti-inflammatoires/pharmacologie , Produits dermatologiques/administration et posologie , Produits dermatologiques/effets indésirables , Produits dermatologiques/pharmacologie , Humains , Nicotinamide/effets indésirables , Nicotinamide/pharmacologie , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...